Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer

Kyle G. Halvorson, Molly A. Sevcik, Joseph R. Ghilardi, Lucy J. Sullivan, Nathan J. Koewler, Frieder Bauss, Patrick W Mantyh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Over half of all chronic cancer pain arises from metastases to bone and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Currently, bone pain is treated primarily by opioid-based therapies, which are frequently accompanied by significant unwanted side effects. In an effort to develop nonopioid-based therapies that could rapidly attenuate tumor-induced bone pain, we examined the effect of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain. Following injection and confinement of green fluorescent protein-transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was administered either as a single dose (300 μg/kg), at Day 7 post-tumor injection, when tumor-induced bone destruction and pain were first evident, or in three consecutive doses (100 μg/kg/day) at Days 7, 8, and 9 post-tumor injection. Intravenous ibandronate administered once or in three consecutive doses reduced ongoing and movement-evoked bone cancer pain-related behaviors, neurochemical markers of central sensitization, tumor burden, and tumor-induced bone destruction. These results support limited clinical trials that suggest the potential of ibandronate to rapidly attenuate bone pain and illuminate the mechanisms that may be responsible for limiting pain and disease progression.

Original languageEnglish (US)
Pages (from-to)289-303
Number of pages15
JournalJournal of Pain and Symptom Management
Volume36
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Central Nervous System Sensitization
Bone Neoplasms
Tumor Burden
Bone and Bones
Pain
Neoplasms
Injections
Inbred C3H Mouse
Diphosphonates
Green Fluorescent Proteins
Chronic Pain
Sarcoma
Intravenous Administration
Femur
Opioid Analgesics
Disease Progression
ibandronic acid
Bone Marrow
Clinical Trials
Neoplasm Metastasis

Keywords

  • bisphosphonates
  • ibandronate
  • nociception
  • skeletal malignancies
  • Tumor bone pain

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer. / Halvorson, Kyle G.; Sevcik, Molly A.; Ghilardi, Joseph R.; Sullivan, Lucy J.; Koewler, Nathan J.; Bauss, Frieder; Mantyh, Patrick W.

In: Journal of Pain and Symptom Management, Vol. 36, No. 3, 09.2008, p. 289-303.

Research output: Contribution to journalArticle

Halvorson, Kyle G. ; Sevcik, Molly A. ; Ghilardi, Joseph R. ; Sullivan, Lucy J. ; Koewler, Nathan J. ; Bauss, Frieder ; Mantyh, Patrick W. / Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer. In: Journal of Pain and Symptom Management. 2008 ; Vol. 36, No. 3. pp. 289-303.
@article{65e39f114c034a86861d37f750800b3e,
title = "Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer",
abstract = "Over half of all chronic cancer pain arises from metastases to bone and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Currently, bone pain is treated primarily by opioid-based therapies, which are frequently accompanied by significant unwanted side effects. In an effort to develop nonopioid-based therapies that could rapidly attenuate tumor-induced bone pain, we examined the effect of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain. Following injection and confinement of green fluorescent protein-transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was administered either as a single dose (300 μg/kg), at Day 7 post-tumor injection, when tumor-induced bone destruction and pain were first evident, or in three consecutive doses (100 μg/kg/day) at Days 7, 8, and 9 post-tumor injection. Intravenous ibandronate administered once or in three consecutive doses reduced ongoing and movement-evoked bone cancer pain-related behaviors, neurochemical markers of central sensitization, tumor burden, and tumor-induced bone destruction. These results support limited clinical trials that suggest the potential of ibandronate to rapidly attenuate bone pain and illuminate the mechanisms that may be responsible for limiting pain and disease progression.",
keywords = "bisphosphonates, ibandronate, nociception, skeletal malignancies, Tumor bone pain",
author = "Halvorson, {Kyle G.} and Sevcik, {Molly A.} and Ghilardi, {Joseph R.} and Sullivan, {Lucy J.} and Koewler, {Nathan J.} and Frieder Bauss and Mantyh, {Patrick W}",
year = "2008",
month = "9",
doi = "10.1016/j.jpainsymman.2007.10.005",
language = "English (US)",
volume = "36",
pages = "289--303",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer

AU - Halvorson, Kyle G.

AU - Sevcik, Molly A.

AU - Ghilardi, Joseph R.

AU - Sullivan, Lucy J.

AU - Koewler, Nathan J.

AU - Bauss, Frieder

AU - Mantyh, Patrick W

PY - 2008/9

Y1 - 2008/9

N2 - Over half of all chronic cancer pain arises from metastases to bone and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Currently, bone pain is treated primarily by opioid-based therapies, which are frequently accompanied by significant unwanted side effects. In an effort to develop nonopioid-based therapies that could rapidly attenuate tumor-induced bone pain, we examined the effect of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain. Following injection and confinement of green fluorescent protein-transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was administered either as a single dose (300 μg/kg), at Day 7 post-tumor injection, when tumor-induced bone destruction and pain were first evident, or in three consecutive doses (100 μg/kg/day) at Days 7, 8, and 9 post-tumor injection. Intravenous ibandronate administered once or in three consecutive doses reduced ongoing and movement-evoked bone cancer pain-related behaviors, neurochemical markers of central sensitization, tumor burden, and tumor-induced bone destruction. These results support limited clinical trials that suggest the potential of ibandronate to rapidly attenuate bone pain and illuminate the mechanisms that may be responsible for limiting pain and disease progression.

AB - Over half of all chronic cancer pain arises from metastases to bone and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Currently, bone pain is treated primarily by opioid-based therapies, which are frequently accompanied by significant unwanted side effects. In an effort to develop nonopioid-based therapies that could rapidly attenuate tumor-induced bone pain, we examined the effect of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain. Following injection and confinement of green fluorescent protein-transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was administered either as a single dose (300 μg/kg), at Day 7 post-tumor injection, when tumor-induced bone destruction and pain were first evident, or in three consecutive doses (100 μg/kg/day) at Days 7, 8, and 9 post-tumor injection. Intravenous ibandronate administered once or in three consecutive doses reduced ongoing and movement-evoked bone cancer pain-related behaviors, neurochemical markers of central sensitization, tumor burden, and tumor-induced bone destruction. These results support limited clinical trials that suggest the potential of ibandronate to rapidly attenuate bone pain and illuminate the mechanisms that may be responsible for limiting pain and disease progression.

KW - bisphosphonates

KW - ibandronate

KW - nociception

KW - skeletal malignancies

KW - Tumor bone pain

UR - http://www.scopus.com/inward/record.url?scp=49749152809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749152809&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2007.10.005

DO - 10.1016/j.jpainsymman.2007.10.005

M3 - Article

C2 - 18411018

AN - SCOPUS:49749152809

VL - 36

SP - 289

EP - 303

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 3

ER -